Research And Markets Research And Markets

Oncology Development Strategies: Considerable Commercial Potential but Specific Needs Must be Addressed

  • ID: 2374545
  • January 2013
  • Region: Global
  • CBR Pharma Insights
1 of 3

The oncology therapeutic area has seen significant development and advances over the last decade. However, oncology has one of the lowest overall clinical success rates of all therapy areas with only a third of oncology drugs that get to Phase III proceeding to approval. There are a number of factors that will affect the likelihood of success in oncology drug development and these must be taken into consideration when designing the clinical development plan. Oncology clinical trials tend to be more complex than those in other therapy areas, largely due to the number of endpoints that can be utilized, the growing need for adaptive trial design and the types of patients that are eligible for the clinical studies. While overall survival is the gold standard endpoint, achieving this is challenging for many oncology trials and other endpoints such as progression-free survival are frequently used as surrogates.

The approval of oncology drugs has been facilitated by regulatory mechanisms that have been put in place to expedite the process for drugs with small patient populations or that address areas of high unmet need. Programs to allow early access to developmental drugs are becoming READ MORE >

Note: Product cover images may vary from those shown
2 of 3

Executive summary


Why is oncology different?

Oncology clinical trials
- Endpoints
- Trial design
- Biomarkers
- Access to patients
- Regional data needs

Regulatory strategies
- Mechanisms in place that can facilitate oncology approvals
- Critical success factors

Effective oncology launch strategies
- Launch sequencing
- Pricing and reimbursement considerations
- Communication planning
- Launching with immature data

- List of sources

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown